We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+59.01%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$720M
AUM Growth
-$21.6M
Cap. Flow
-$169M
Cap. Flow %
-23.52%
Top 10 Hldgs %
49.7%
Holding
103
New
21
Increased
18
Reduced
27
Closed
35

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$23.5M
2
IMNM icon
Immunome
IMNM
+$19.8M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.1M
4
COGT icon
Cogent Biosciences
COGT
+$12.1M
5
PFE icon
Pfizer
PFE
+$10.6M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$36.8M
2
AKRO
Akero Therapeutics
AKRO
+$30.6M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$24.8M
4
INSM icon
Insmed
INSM
+$24.7M
5
CDTX
Cidara Therapeutics
CDTX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
76
DELISTED
Cidara Therapeutics
CDTX
– –
-220,902
Closed -$21.2M
COGT icon
77
CALL
Cogent Biosciences
COGT
$6.65B
– –
-360,000
Closed -$5.17M
CRNX icon
78
Crinetics Pharmaceuticals
CRNX
$8.84B
– –
-50,000
Closed -$2.08M
CYTK icon
79
Cytokinetics
CYTK
$10.5B
– –
-211,000
Closed -$11.6M
DCTH icon
80
Delcath Systems
DCTH
$422M
– –
-203,386
Closed -$2.19M
DYN icon
81
Dyne Therapeutics
DYN
$4.7B
– –
-100,000
Closed -$1.26M
ELVN icon
82
Enliven Therapeutics
ELVN
$3.92B
– –
-10,675
Closed -$219K
EYPT icon
83
EyePoint Inc
EYPT
$1.03B
– –
-230,837
Closed -$3.29M
IMVT icon
84
Immunovant
IMVT
$7.93B
– –
-50,000
Closed -$806K
KNSA icon
85
Kiniksa Pharmaceuticals
KNSA
$5.8B
– –
-88,910
Closed -$3.45M
MLTX icon
86
CALL
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-65,000
Closed -$466K
MLTX icon
87
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-30,000
Closed -$215K
MODD icon
88
Modular Medical
MODD
$12.9M
– –
-21,318
Closed -$448K
MRSN
89
DELISTED
Mersana Therapeutics
MRSN
– –
-133,636
Closed -$1.04M
NKTR icon
90
Nektar Therapeutics
NKTR
$2.39B
– –
-365
Closed -$20.8K
PHVS icon
91
Pharvaris
PHVS
$2.28B
– –
-183,903
Closed -$4.59M
RARE icon
92
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-25,000
Closed -$752K
RNAM
93
DELISTED
Avidity Biosciences
RNAM
– –
-844,633
Closed -$36.8M
SNDX icon
94
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-50,000
Closed -$770K
SRRK icon
95
Scholar Rock
SRRK
$5.67B
– –
-233,920
Closed -$8.71M
UTHR icon
96
PUT
United Therapeutics
UTHR
$25.8B
– –
-59,900
Closed -$25.1M
VSTM icon
97
Verastem
VSTM
$510M
– –
-1,042,757
Closed -$9.21M
ZURA icon
98
Zura Bio
ZURA
$516M
– –
-720,452
Closed -$3.12M
BBOT
99
BridgeBio Oncology
BBOT
$648M
– –
-457,414
Closed -$5.3M
ATYR
100
PUT
aTyr Pharma
ATYR
$47.6M
– –
-1,250,000
Closed -$901K
1 2 3
4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Silverarc Capital Management held 103 positions worth $720M, down 2.9% from $742M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management withdrew a net $169M in Q4 2025, closing 35 positions and reducing 27 holdings. Its most notable exit was Avidity Biosciences, an estimated $36.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Immunome worth $24.2M.

  • Silverarc Capital Management's largest Q4 2025 buy was Immunome: 1,126,210 shares worth $24.2M.
  • Silverarc Capital Management added most to Celcuity in Q4 2025, an estimated $23.5M increase.
  • Silverarc Capital Management's biggest Q4 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $24.8M.
  • Silverarc Capital Management fully exited Avidity Biosciences in Q4 2025, selling an estimated $36.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $720M portfolio in Q4 2025.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q4 2025.
  • Silverarc Capital Management's portfolio value fell 2.9% quarter-over-quarter to $720M.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.